Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Total Non-Current Liabilities (2021 - 2025)

Historic Total Non-Current Liabilities for HCW Biologics (HCWB) over the last 5 years, with Q3 2025 value amounting to $26.9 million.

  • HCW Biologics' Total Non-Current Liabilities changed N/A to $26.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.9 million, marking a year-over-year change of. This contributed to the annual value of $37.0 million for FY2024, which is 14698.43% up from last year.
  • Latest data reveals that HCW Biologics reported Total Non-Current Liabilities of $26.9 million as of Q3 2025.
  • In the past 5 years, HCW Biologics' Total Non-Current Liabilities ranged from a high of $37.0 million in Q4 2024 and a low of $1.1 million during Q2 2022
  • Over the past 5 years, HCW Biologics' median Total Non-Current Liabilities value was $10.9 million (recorded in 2023), while the average stood at $15.2 million.
  • The largest annual percentage gain for HCW Biologics' Total Non-Current Liabilities in the last 5 years was 85213.23% (2023), contrasted with its biggest fall of 3441.26% (2023).
  • Over the past 5 years, HCW Biologics' Total Non-Current Liabilities (Quarter) stood at $2.3 million in 2021, then skyrocketed by 303.45% to $9.4 million in 2022, then soared by 59.97% to $15.0 million in 2023, then skyrocketed by 146.98% to $37.0 million in 2024, then dropped by 27.42% to $26.9 million in 2025.
  • Its last three reported values are $26.9 million in Q3 2025, $27.2 million for Q2 2025, and $34.8 million during Q1 2025.